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According to the cancer stem cell hypothesis tumors are maintained by a cancer stem cell population which is able to initiate
and maintain tumors. Tumor-initiating stem cells display stem or progenitor cell properties such as self-renewal and capacity to
re-establish tumors that recapitulate the tumor of origin. In this paper, we discuss data relative to the presence of cancer stem cells
in human renal carcinoma and their possible origin from normal resident stem cells. The cancer stem cells identiﬁed in human
renal carcinomas are not derived from the normal CD133+ progenitors of the kidney, but rather from a more undiﬀerentiated
population that retains a mesenchymal phenotype. This population is able to self-renewal, clonogenicity, and in vivo tumor
initiation.Moreover,theyretainpluripotentdiﬀerentiationcapability,astheycangeneratenotonlytheepithelialcomponentofthe
tumor, but alsotumorendothelialcells. This suggests that renal cancer stem cells maycontribute to the intratumorvasculogenesis.
1.Introduction
Emerging evidence showed that the capacity of a tumor to
grow and propagate resides in a small population of tumor
low proliferating cells, termed cancer stem cells (CSCs) or
tumor-initiating cells [1]: the cancer stem cell hypothesis
suggests that tumors are maintained by a CSC population
which is chemo- and radioresistant and therefore can persist
after treatment, leading to tumor recurrence [2, 3].
A tumor-initiating population able to sustain and main-
tain the tumor growth was identiﬁed in the majority of solid
tumors [4–14]. These stem-like cells are identiﬁed by their
abilitytogiverise tonewserially transplantabletumors when
xenografted in small number into immunodeﬁcient mice,
and to display stem or progenitor cell properties. In particu-
lar, they are characterized by self-renewal and capacity to re-
establishtumorthatrecapitulatesthetumoroforigin,thanks
to the ability to undergo asymmetric division leading to the
generation of a progeny that can diﬀerentiate to produce
tumor cells with heterogeneous phenotype [3].
Renal carcinoma is a common form of urologic tumor,
representing 3% of total human malignancies, with a high
metastatic index at the diagnosis and a high rate of relapse
because of the resistance to radiations and chemotherapies
[15]. Due to the ability of CSCs to recapitulate the tumor,
strategies of targeting CSCs should be taken into account.
Recent encouraging data in other tumors have provided
proof of principle that selective targeting of CSCs is possible
[16–18].
In this paper, we will present the existing data of the
literature on therole ofstem cellsin human renal carcinoma.
Normal stem cells may participate to renal carcinomas,
sustaining tumor growth and vascularization. In addition,
tumor stem cells with tumor-initiating ability have been
described (Table 1), suggesting the relevance of CSCs in
generation, growth, and recurrence of renal carcinomas.
Finally, evidences will be presented on the ability of renal
CSCs to diﬀerentiate into endothelial cells and to participate
to tumor vasculogenesis.
2.CancerStemCell Hypothesisfor
Tumor Origin
The concept of a less diﬀerentiated, pluripotent cell forming
cancerreliesoncommonpropertiesandphenotypeoftumor
stem cells and embryonic or adult normal stem cells. This
could be due to acquirement of stem cell properties by fully2 International Journal of Nephrology
diﬀerentiated proliferating cells following accumulation of
critical mutations or alternatively to the origin of CSCs from
mutated normal stem cells. Several evidences support both
possibilities [19, 20]. It has been shown that the epithelial-to
mesenchymal transition of tumors enhances the number of
CSCs [21], supporting the notion that the dediﬀerentiation
process may favor the stem-related phenotype of tumors.
Indeed, recent studies showing that activation of critical em-
bryonic genes or oncogenes may induce pluripotency in
diﬀerentiated cells [22] further support this possibility.
Other evidences support the notion that tumorigenesis
may originate from mutation of normal adult tissue resident
stem cells or from deriving progenitor cells that have
acquired mutations that enable them to escape from niche
control [23]. Alternatively, deregulation of extrinsic factors
within the niche might lead to uncontrolled proliferation of
stem cells and tumorigenesis. This concept is supported ﬁrst
by the fact that stem cells have, or can, reacquire the self-
renewal properties needed for maintaining and expanding
stem cell numbers [24]. Second, the stem cell pool is
anchored to the niche and is maintained through the entire
life and therefore may have the time to acquire mutations
[25]. This is particularly pertinent to cancers of continually
renewing cell populations, such as those of the intestine,
stomach, and skin [26, 27]. Under this light, it can be pro-
posed that cancers may represent a maturation arrest of stem
cells. Depending on the diﬀerentiative state of the mutated
cell,fromstemtoprogenitortodiﬀerentiatedcells,CSCsmay
display diﬀerent stem properties and malignancy.
3.Normal RenalStemCells
According to the hierarchical lineage view of tumors [20],
renal tumors may arise from the embryonic stem cell com-
partment, giving rise to the Wilm’s tumor, as well as
from the stem cell pool of the adult kidney or from the
deriving progenitors, giving rise to the diﬀerent histologic
types of carcinomas (undiﬀerentiated, clear-cell, papillary
carcinomas) (Figure 1). Embryonic stem cells have been
described in the embryonic kidney until relatively late in
g e s t a t i o ni nt h en e p h r o g e n i cz o n e ,f r o mw h i c ht h e yh a v e
beenisolatedandcharacterized [28].Comparativeanalysisof
embryonic stem cells and of the pediatric renal malignancy
Wilm’s tumor showed that Wilm’s tumor resulted from a
diﬀerentiation arrest of embryonic progenitors committed
to the nephrogenic lineage [29]. These cells were present in
the tumor both as undiﬀerentiated blastema and as renal
diﬀerentiated elements.
In the human adult kidney, CD133+ renal progenitor
cellshavebeen characterized byourgroup in the renal cortex
from the tubule/interstitium [30]. In addition, multipotent
CD133+/CD24+ stem cells have been isolated from the
Bowman’scapsule[31].Agenomiccharacterizationofmulti-
potentCD133+/CD24+ renal progenitorcellsfromglomeruli
and tubules of adult human kidney revealed no signiﬁcant
diﬀerences in the gene expression patterns suggesting that
tubular and glomerular renal progenitor cells represent a
genetically homogeneous population [32]. Indeed, the pres-
ence of cytokeratin expression by the CD133+/CD24+ cells
Table 1: Diﬀerent populations of stem cells identiﬁed in human
renal carcinomas and role in tumor growth. N. D.: not done.
Identiﬁcation method Role in carcinogenesis References
Expression of CD105
Tumor initiation
Endothelial
diﬀerentiation
Bussolatiet al.
[36]
Expression of CD133
Nontumor initiation
Promotionof tumor
growth and
vascularization
Bruno et al. [33]
Side population N.D. Addla et al. [37]
Huges et al. [38]
Sphere formation
Tumor initiation
Radio- and
chemoresistance
Zhonget al. [39]
suggests an epithelial commitment that characterizes these
cells as epithelial progenitors.
4.CD133+/CD34− CellsandRenalCarcinomas
Following the stem cell view of tumor generation, CD133
has been investigated as a marker for identiﬁcation of CSCs
in renal carcinomas. A small population of CD133+/CD34−
cells (less than 1% of the total cells) was found in human
renal carcinomas [33]. These cells, that represent a pro-
genitor cell population in the normal kidney [30], showed
the same mesenchymal phenotype and diﬀerentiative ability
of their normal counterpart. They expressed CD73, CD44,
CD29, the developmental renal marker PAX-2, and the
mesenchymal marker vimentin and were able to diﬀerentiate
both in endothelial and epithelial cells in vitro and in vivo
[33].Wheninjectedsubcutaneouslywithin Matrigelinimm-
unodeﬁcient mice, CD133+/CD34− stem cells were not able
to form tumors suggesting that they did not represent the
tumor-initiating cell population [33], at variance of CD133+
cells derived from brain, prostate and pulmonary tumors
[5, 10, 13, 34]. The observation that CD133+/CD34− cells
cultured in presence of the tumor supernatant diﬀerentiated
in endothelial cells led to the idea that the tumor microenvi-
ronment could be involved in the endothelial commitment
of these renal progenitors. Indeed, when cotransplanted
with renal tumor cells, at a 1:100 ratio, CD133+/CD34−
cells signiﬁcantly enhanced tumor engraftment, growth,
and vascularization, suggesting that these progenitors may
produceagrowthfactorenvironmentfavoringtumorgrowth
and vascularization [33]. Recently, D’Alterio et al. evaluated
theexpression ofCD133onsamplesofhumanrenalclearcell
carcinoma, showing that CD133 expression did not correlate
toclinicalpathologicalfeaturesoraﬀectedpatientsprognosis
[35].
5.CD105+ RenalCancerStemCells
We recently identiﬁed a population of CD105+ tumor-
initiating cells in renal human carcinomas [36]. The mesen-
chymal origin of these cells is in accordance with theInternational Journal of Nephrology 3
Embryonic renal stem cell
Embryonic stem cell Teratocarcinoma
Wilm’s tumor
Peritubular or tubular adult
renal progenitor cell
(mesenchymal phenotype)
Undiﬀerentiated carcinoma
Papillary carcinoma Tubular adult cell with
a plastic phenotype
Tubular cell
CD105
CD133
G1
Clear-cell carcinoma
Figure 1: Scheme representative of the possible stem cell origin of renal CSCs. Mutations/epigenetic alterations of the renal embryonic stem
cells may originate the pediatric malignancy Wilm’s tumor. The diﬀerent histologic types of renal carcinomas of the adult may derive from
mutations occurring in the stem cell compartment of the adult kidney. The lack of CD133+ marker in renal CSCs may support the idea
of an origin from a yet unidentiﬁed mesenchymal population, which is ahead of CD133+ renal progenitors in the diﬀerentiation linage.
Alternatively, a process of de-diﬀerentiation of renal progenitors or mature cells could be involved.
mesenchymaloriginofthekidneyandwiththemesenchymal
phenotype of stem cells found in normal rodent kidney
as well as in the human embryo [40–42]. By magnetic
cell sorting of specimens of human renal carcinomas, our
laboratory isolated a subpopulation of cell expressing the
mesenchymal marker CD105, representing less than 10% of
the tumor mass. The CD105+ population induced tumors in
SCID mice with 100% incidence, whereas the CD105− pop-
ulation induced tumors with only 10% incidence. CD105+
cells expressed markers characteristic of mesenchymal stem
cells, such as CD44, CD90, CD146, CD73, CD29, and
vimentin. Characterization of the phenotype of CD105+
clones revealed several stem cells properties, such as clono-
genicability,sphereformationinpresenceofnonadhesivecell
culture medium, expression of stem cells markers (Nanog,
Oct4, Musashi, Nestin, and the embryonic marker Pax2),
lack of diﬀerentiative epithelial markers, in vitro diﬀeren-
tiation on both endothelial and epithelial cell types [36].
In addition, in vivo they generated serially transplantable
carcinomas containing a small population of undiﬀerenti-
ated CD105+ tumorigenic cells and diﬀerentiated CD105−
tumor epithelial cells. Only the CD105+ population was able
to propagate the tumor [36]. These data suggest that the
CD105+ cells represent a tumor-initiating cell population
that may originate from resident renal stem cells with
mesenchymal characteristics. The lack of CD133 and CD24
expression, which are present in adult and embryonic renal
progenitors [30, 31, 43] by tumor-initiating CD105+ clones,
suggests that they are not derived from the CD133+ pop-
ulation. Moreover, CD133+ progenitors previously isolated
from renal tumors did not express CD105 and were not
tumorigenic [33].
6.Sphere-DerivedCSCs
Generation of spheres is considered a useful culture system
to select for CSCs. Cells growing as tumor spheres in serum-
free medium supplemented with EGF and bFGF were
isolated from the renal cell carcinoma cell line SK-RC-42.
This sphere-forming population showed the ability of self-
renewing in vitro and in vivo, higher mRNA expression
levels of several “stemness” genes, stronger tumorigenicity
and resistance to chemotherapeutic agents and irradiation
compared with the monolayer adherent cells [39].
7.SidePopulationin RenalCarcinomas
Accordingto the fact that the isolation of CSCsusing speciﬁc
markers can be very diﬃcult, Addla et al. identiﬁed a side
population (SP) from both normal and malignant renal
epithelial cells [37], using the Hoechst 33342 dye eﬄux assay
developed by Goodell et al. in the hematopoietic system
[44]. The SP of normal kidney expresses the same markers
identiﬁed by Bussolati et al. [30]. In addition, the authors
found a diﬀerential expression of CD133 marker between4 International Journal of Nephrology
the side population of normal and malignant kidney, being
CD133 only expressed by the normal SP. According to
t h e s eﬁ n d i n g s ,t h el o s so fC D 1 3 3m i g h tb eav e r ye a r l y
event in stem cells diﬀerentiation and possibly in malignant
transformation [37]. The characterization of SP cells with
high brilliance synchrotron-FITR spectroscopy revealed the
presence of diﬀerent subpopulations of cells, with diﬀerent
cellular biochemistry [38], but actually there is no evidence
of a diﬀerential role of these subpopulations in carcinogene-
sis, neither any speciﬁc marker has been identiﬁed.
8.RenalCSCsand EndothelialDifferentiation
T h es t e m n e s sa n dt h eo r i g i no fC S C sf r o mt i s s u es t e m /
progenitor cells may support the capacity of CSCs to dif-
ferentiate in cell types present in the tumor other than the
epithelial tumor cells. In renal carcinomas CD105+ CSCs
were shown to be bipotent, as they were able to diﬀerentiate
into tumor epithelial and endothelial cells both in vitro
and in vivo [36] .T h ee v i d e n c eo fa ni nv i v od i ﬀerentiation
of stem cells into endothelial cells was provided by the
observation that at least a fraction of the vessels present in
the transplanted tumors originated from tumor stem cells
were of human origin. Clonal studies showing endothelial
diﬀerentiation of single-cell-derived spheres or clonal cell
lines derived from renal CSCs conﬁrmed the multipotency
of renal CSCs. This endothelial diﬀerentiation has been also
shown for CSCs derived from glioblastomas [45–48], hep-
atocellular carcinomas [49], ovarian [50] and breast cancer
[51], suggesting that this is rather a general phenomenon
applicable to stem cells in diﬀerent tumors, possibly due
to the maintenance of stem properties in cancer stem cells.
Of interest, a mechanism involved in the endothelial diﬀer-
entiation of tumor stem cells was reported to be hypoxia
[51]. This concept is of particular relevance in tumor antian-
giogenic therapy, as therapy-induced hypoxia may promote
alternative strategies to support tumor vascularization and
induce a switch from normal to cancer stem-dependent
vascularization. Anti-angiogenic therapies currently implied
in the treatment of renal carcinoma [52] should therefore
be aimed to target not only normal, but also tumor-derived
endothelial cells.
9.Conclusions
Altogether the data of the literature indicate that renal car-
cinomas possess a population of CSCs with mesenchymal
properties (Table 1). These CSCs have a high tumorigenic
abilityand are resistant to chemo- and radiotherapy [36, 39].
In addition, the diﬀerentiation of CSCs into endothelial
cells and the possible role of inﬁltrating normal stem cells,
such as CD133+ resident cells and MSCs, suggest a complex
relationship between tumor and its microenvironment, that
should be taken into account for the design of future
therapies.
Concerning the stem cell origin of renal CSCs, the data
are still discordant. The lack of tumorigenicity of CD133+
cells [33] is in contrast with the idea that, also in the kidney,
carcinomas originate from renal progenitors expressing
CD133. A possible explanation is the origin of renal carci-
nomas from a more undiﬀerentiated stem cell compartment
(Figure 1). Alternatively, it could be postulated that a true
stem cell compartment is lacking in the renal tubuli. In
particular, the plastic phenotype of tubular cells, evidenced
by the ﬁnding that they are in the G1 phase of the cell
cycle [53], can suggest that tubular cells may modulate their
phenotype toward stemness in response to environmental
stimuli. According to this idea, being the kidney a low
regenerating organ, a diﬀerent mechanism could occur
in respect to highly proliferating organs such as the gut
implying the de-diﬀerentiation of mature cells.
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